These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37030459)

  • 41. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy.
    Feng Q; Ma X; Cheng K; Liu G; Li Y; Yue Y; Liang J; Zhang L; Zhang T; Wang X; Gao X; Nie G; Zhao X
    Adv Mater; 2022 Oct; 34(40):e2206200. PubMed ID: 35985666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.
    Tang XX; Shimada H; Ikegaki N
    Curr Oncol; 2024 Jun; 31(6):3212-3226. PubMed ID: 38920727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
    Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD47: role in the immune system and application to cancer therapy.
    Hayat SMG; Bianconi V; Pirro M; Jaafari MR; Hatamipour M; Sahebkar A
    Cell Oncol (Dordr); 2020 Feb; 43(1):19-30. PubMed ID: 31485984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-SIRP
    Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
    JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
    Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
    Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis.
    Park HR; Kim SE; Keam B; Chung H; Seok SH; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    Sci Rep; 2022 Jul; 12(1):12546. PubMed ID: 35869130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
    Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
    Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy.
    Nie W; Wu G; Zhang J; Huang LL; Ding J; Jiang A; Zhang Y; Liu Y; Li J; Pu K; Xie HY
    Angew Chem Int Ed Engl; 2020 Jan; 59(5):2018-2022. PubMed ID: 31746532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
    Yang H; Shao R; Huang H; Wang X; Rong Z; Lin Y
    Cancer Med; 2019 Aug; 8(9):4245-4253. PubMed ID: 31183992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 58. Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer.
    Tan Y; Chen H; Zhang J; Cai L; Jin S; Song D; Yang T; Guo Z; Wang X
    Eur J Med Chem; 2022 Feb; 229():114047. PubMed ID: 34915428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
    Zhu D; Hadjivassiliou H; Jennings C; Mikolon D; Ammirante M; Acharya S; Lloyd J; Abbasian M; Narla RK; Piccotti JR; Stamp K; Cho H; Hariharan K
    MAbs; 2024; 16(1):2310248. PubMed ID: 38349008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.